Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation
Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 776-785
DOI: 10.1093/ndt/gfaf207 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 03.10.2025. Verfasst von Cal H Robinson und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Calcineurin Inhibitors, Immunosuppressive Agents, Rituximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Cure Glomerulonephropathy, Women's College Hospital Research Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Children and young adults with nephrotic syndrome are commonly treated with steroid-sparing immunosuppressive medications. Rituximab is increasingly used in frequently relapsing disease, but the real-world comparative effectiveness of rituximab and calcineurin inhibitors is unclear.
Methods
Using target trial methods, we emulated a pragmatic randomized controlled trial using observational data from two prospective nephrotic syndrome cohorts. We included children and adults (aged 1–40 years) with steroid-sensitive nephrotic syndrome that first initiated rituximab or calcineurin inhibitor treatment during follow-up. Randomization was emulated using overlap weighting of propensity scores for treatment assignment. The primary outcome was time-to-relapse, analyzed by weighted Cox proportional hazards models. Secondary outcomes were relapse counts, subsequent immunosuppressive treatment, kidney function, hypertension and all-cause mortality.
Results
Of 372 eligible participants, 104 initiated rituximab and 268 initiated calcineurin inhibitors. Baseline characteristics were balanced after propensity score weighting. Mean age at medication initiation was 13.2 years, 61% were male and 69% had received prior steroid-sparing medications. Throughout a median 4.9-year (quartile 1–3, 2.0–7.2) follow-up, relapses occurred in 58 participants (56%) treated with rituximab and 209 (78%) treated with calcineurin inhibitors. There was no significant difference in time-to-relapse after rituximab vs calcineurin inhibitor treatment [weighted hazard ratio (HR) 0.90, 95% confidence interval (CI) 0.59–1.38]. There were also no significant differences in relapse rates or kidney function decline. Participants treated with rituximab were at lower risk of developing hypertension (weighted HR 0.24, 95% CI 0.08–0.79).
Conclusions
Using real-world data, there was no difference in relapse rates after rituximab vs calcineurin inhibitors among children and young adults with steroid-sensitive nephrotic syndrome. Steroid-sparing immunosuppression selection should be a shared decision, considering medication-specific side effects, costs, access, duration and adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, The University of Toronto, Toronto, Ontario, Canada.
- Division of Biostatistics, Dalla Lana School of Public Health, The University of Toronto, Toronto, Ontario, Canada.
- Department of Statistical Science, University College London, London, UK.
- Division of Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Cal H Robinson, Anna Heath, Jason Kidd
Förderung
- NIDDK NIH HHS
- Cure Glomerulonephropathy
- Women's College Hospital Research Institute
- Kidney Foundation of Canada KRESCENT Program
- Canadian Institutes of Health Research Fellowship
- Women’s College Hospital Research Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Robinson, C. H., Heath, A., Greenbaum, L. A., Hladunewich, M. A., Aman, N., Banh, T. H. M., Brooke, J., Canetta, P., Cara-Fuentes, G., Dhillon, V., Garner, M., Helmuth, M., Kidd, J., Larkina, M., Licht, C., McKay, A., Pearl, R., Radhakrishnan, S., Reidy, K., …, & Parekh, R. S. (2026). Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation. Nephrology Dialysis Transplantation, 41(4), 776-785. https://doi.org/10.1093/ndt/gfaf207
Vancouver
Robinson CH, Heath A, Greenbaum LA, Hladunewich MA, Aman N, Banh THM, et al. Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation. Nephrology Dialysis Transplantation. 2026;41(4):776-785. doi:10.1093/ndt/gfaf207
BibTeX
@article{Robinson2026,
author = {Robinson, Cal H and Heath, Anna and Greenbaum, Larry A and Hladunewich, Michelle A and Aman, Nowrin and Banh, Tonny H M and Brooke, Josefina and Canetta, Pietro and Cara-Fuentes, Gabriel and Dhillon, Vaneet and Garner, Mackenzie and Helmuth, Margaret and Kidd, Jason and Larkina, Maria and Licht, Christoph and McKay, Ashlene and Pearl, Rachel and Radhakrishnan, Seetha and Reidy, Kimberly and Selvathesan, Nithiakishna and Teoh, Chia Wei and Vasilevska-Ristovska, Jovanka and Parekh, Rulan S},
title = {Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
volume = {41},
number = {4},
pages = {776--785},
doi = {10.1093/ndt/gfaf207}
}
EUVIMED